Medtronic sells off snoring implant division; B Braun gains CE mark for coronary artery stenosis stent;

@FierceMedDev:vIsrael's Lumenis is plowing ahead with a planned $100M IPO--device market wariness be damned. Story | Follow @FierceMedDev

@MarkHFierce: Philips scored a strategically smart remote patent monitoring deal with Boston's Partners Healthcare. Article | Follow @MarkHFierce

@MichaelGFierce: This week's Chutes&Ladders: Ex-Gilead Irish operations leader joins Alexion to expand in Dublin, Athlone. Report | Follow @MichaelGFierce

@EmilyWFierce: No love for Aveo and Astellas: Companies 'breakup,' end pact to develop cancer drug. Article | Follow @EmilyWFierce

> Medtronic ($MDT) has quietly sold off a division that manufactured a medical device implant designed to treat snoring. Story

> B. Braun won a CE mark for a new stent designed to treat coronary artery stenosis. Item

> An ad featuring the surgery team from the University of Illinois Hospital promoting the use of Intuitive Surgical's ($ISRG) da Vinci surgical robot continues to generate controversy. Blog

> Money-losing Missouri medical device maker Stereotaxis ($STXS) made chairman William Mills III its new CEO. Story

> The U.S. FDA cleared a new catheter designed for the rectal delivery of medications and liquids, useful when patients are unable to swallow. Item

Biotech News

@FierceBiotech: Follow the money: Our John Carroll talks money, geography and biotech. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Rare-disease powerhouse Alexion grabs an option on muscular dystrophy buyout. More | Follow @JohnCFierce

@DamianFierce: Astellas finally bails on $AVEO, giving up on the thrice-failed tivozanib. Story | Follow @DamianFierce

@EmilyMFierce: BioLineRx shows effectiveness of leukemia drug in preclinical study. Article via FierceBiotech Research | Follow @EmilyMFierce

> AstraZeneca may have a gout blockbuster on its hands with lesinurad. Story

> GlaxoSmithKline eyes rare disease to widen its respiratory lead. Piece

Pharma News

@FiercePharma: Here's why a crowdfunded HIV vaccine project is drawing criticism from some scientists. More | Follow @FiercePharma

@TracyStaton: Gilead won't make hep C sales projections, but doesn't mind if you do. Provided they're huge. Piece| Follow @TracyStaton

@EricPFierce: CEO Bresch's moves in India give Mylan low-cost production tied to a high-value rep. Report | Follow @EricPFierce

@CarlyHFierce: Shire steers Vyvanse toward binge eating as earnings come up aces. Article | Follow @CarlyHFierce

> Doxycycline sales power Hikma, but the party may be ending. News

> No FDA love for Xarelto in ACS patients. Story